Form 4: Barinthus Biotherapeutics Director Acquires Options
SEC Form 4 Filing
Director Alex Hammacher acquired options to purchase 19,516 ordinary shares of Barinthus Biotherapeutics plc. on May 10, 2024.
Summary
- On May 10, 2024, Alex Hammacher, a director of Barinthus Biotherapeutics plc., acquired options to purchase 19,516 ordinary shares.
- The exercise price of these options is $2.34 per share.
- The options vest fully on the earlier of May 10, 2025, or the next annual meeting of shareholders, contingent upon continued service as a director.
- The options expire on May 10, 2034.
- The reporting person directly owns 19,516 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a standard transaction of a director acquiring options, which can be seen as a sign of confidence, but it's not overwhelmingly positive.
Positives
- A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where equity compensation is frequently used.
Stakeholder Impact
- The acquisition of options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/10/2024 | Date of the transaction: Alex Hammacher acquired options. |
| 05/10/2025 | Earliest vesting date for the options, contingent on continued service. |
| 05/10/2034 | Expiration date of the options. |
| 05/14/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.